Pancreatic Cancer Research

ResearcherKyoto UniversityActive in the last 2 years

Hiroshi Seno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8509-8128; OpenAlex author ID A5008788188, A5158177666. Sources: OpenAlex.

Their work

Papers
23 (first author 0, last author 16)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers · 2025: 2 papers · 2026: 4 papers

Papers 23

  1. Corrigendum to Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Last author DOI 10.1172/jci206371↗
  2. FRET imaging of ERK activity in an orthotopic xenograft model of patient-derived pancreatic ductal adenocarcinoma using imaging window. Co-author DOI 10.1242/jcs.265075↗
  3. Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Cancer. Last author DOI 10.3390/cancers18071177↗
  4. Epigenetic Control of Spatiotemporal Dynamics of Pancreatic Cancer Cells via Brg1–Rac1 Signaling Co-author DOI 10.64898/2026.05.04.722641↗
  5. Quantitative Live Imaging Reveals Phase Dependency of PDAC Patient-Derived Organoids on ERK and AMPK Activity. Co-author DOI 10.1111/cas.16439↗
  6. Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Last author DOI 10.1172/jci177533↗
  7. Near-infrared photoimmunotherapy as a complementary modality to in situ vaccine in a preclinical pancreatic cancer model. Last author DOI 10.1016/j.bbrc.2024.150534↗
  8. Reduction of butyrate-producing bacteria in the gut microbiome of Japanese patients with pancreatic cancer. Last author DOI 10.1016/j.pan.2024.09.002↗
  9. Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. Last author DOI 10.1038/s41416-024-02794-5↗
  10. Wnt-deficient and hypoxic environment orchestrates squamous reprogramming of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41556-024-01498-5↗
  11. Concomitant occurrence of pancreatic cancer during long-term follow-up for serous neoplasms. Last author DOI 10.1007/s10396-023-01327-6↗
  12. Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway. Last author DOI 10.1038/s41388-023-02716-4↗
  13. Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer. Co-author DOI 10.1186/s12885-022-09619-9↗
  14. The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma. Last author DOI 10.1111/cas.14768↗
  15. SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2. Co-author DOI 10.1111/cas.15162↗
  16. Correction: CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-21-1255↗
  17. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging. Last author DOI 10.7554/elife.55117↗
  18. CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-19-2745↗
  19. Promoter-Level Transcriptome Identifies Stemness Associated With Relatively High Proliferation in Pancreatic Cancer Cells. Last author DOI 10.3389/fonc.2020.00316↗
  20. Paraplegia as an initial manifestation of pancreatic cancer. Co-author DOI 10.1002/jgh3.12194↗
  21. Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice. Last author DOI 10.1136/gutjnl-2017-315425↗
  22. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. Last author DOI 10.1053/j.gastro.2018.03.039↗
  23. Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report. Last author DOI 10.1097/md.0000000000009217↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akihisa Fukuda · 14 shared papers, 2018–2026 · strength 2.21
  2. Takahisa Maruno · 11 shared papers, 2018–2026 · strength 1.50
  3. Motoyuki Tsuda · 9 shared papers, 2018–2026 · strength 1.13
  4. Etsuro Hatano · 6 shared papers, 2022–2026 · strength 1.06
  5. Toshihiko Masui · 7 shared papers, 2017–2026 · strength 1.05
  6. Makoto Sono · 6 shared papers, 2019–2026 · strength 0.97
  7. Munenori Kawai · 5 shared papers, 2021–2026 · strength 0.91
  8. Kei Iimori · 4 shared papers, 2024–2026 · strength 0.77
  9. Osamu Araki · 5 shared papers, 2018–2026 · strength 0.76
  10. Akihito Machinaga · 3 shared papers, 2024–2026 · strength 0.67
  11. Dieter Saur · 4 shared papers, 2021–2026 · strength 0.64
  12. Satoshi Ogawa · 5 shared papers, 2018–2026 · strength 0.63
  13. Yuzo Kodama · 5 shared papers, 2017–2024 · strength 0.63
  14. Shinji Üemoto · 5 shared papers, 2018–2022 · strength 0.53
  15. Toshihiro Morita · 4 shared papers, 2020–2026 · strength 0.53
  16. Toru Hiratsuka · 2 shared papers, 2025–2026 · strength 0.52
  17. Shujiro Yazumi · 3 shared papers, 2019–2026 · strength 0.48
  18. Shigeo Takaishi · 4 shared papers, 2019–2022 · strength 0.47
  19. Tsutomu Chiba · 5 shared papers, 2018–2021 · strength 0.43
  20. Tomoaki Matsumori · 3 shared papers, 2020–2023 · strength 0.42
  21. Kozo Ikuta · 4 shared papers, 2018–2024 · strength 0.38
  22. Kazuyuki Nagai · 2 shared papers, 2024–2026 · strength 0.38
  23. Akihisa Yamamoto · 1 shared paper, 2026 · strength 0.36
  24. Motomu Tanaka · 1 shared paper, 2026 · strength 0.36
  25. Kosuke Minaga · 2 shared papers, 2024–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.